ADVATE® [Antihemophilic Factor (Recombinant)]

Please see the ADVATE® [Antihemophilic Factor (Recombinant)] Selected Important Risk Information and full Prescribing Information.

Read the full article here

Source: www.advatepro.com

Categories: Hem/Oncs, General Medicine News

Tweets with this article

Med Peds Hospitalist

What is Advate? Plasma/albumin-free recombinant factor VIII replacement therapy for patients with hemophilia A. https://t.co/2Axvsyy7yg

Neuroendocrine Tumor-Associated Chromogranin A Tubulopathy

A 68-year-old male with type 2 diabetes mellitus presented to his primary care physician’s office with worsening bipedal edema, unintentional weight loss, and new-onset serum…

Tim Brown December 26, 2024

Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database

PurposeData that guide selection of optimal local ablative therapy for the management localized hepatocellular carcinoma (HCC) are lacking. Because there are limited prospective comparative data…

Thor Halfdanarson December 26, 2024

Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience

AbstractBackground. Sarcomatoid carcinomas (SC) are rare tumors with both epithelial and mesenchymal characteristics, linked to aggressive behavior and poo

Thor Halfdanarson December 26, 2024

A Scoping Review of the Current Knowledge of the Social Determinants of Health and Infectious Diseases (Specifically COVID-19, Tuberculosis, and H1N1 Influenza) in Canadian Arctic Indigenous Communities

Social determinants of health (SDHs) and the impact of colonization can make Canadian Arctic Indigenous communities susceptible to infectious diseases, including the coronavirus disease 2019…

Dr Henry December 26, 2024

Related Articles